期刊文献+

血栓弹力图评估心脑血管疾病抗血小板药物使用疗效的影响因素 被引量:6

Influencing factors of medication efficacy of antiplatelet drugs in patients with cardiovascular and cerebrovascular diseases based on thromboelastogram
原文传递
导出
摘要 目的探讨心脑血管疾病患者抗血小板药物使用疗效的影响因素。方法选取2020年4月—2021年4月在南京医科大学第一附属医院进行血栓弹力图(TEG)血小板图检测的心脑血管患者363例,根据用药种类和剂量分为A、B、C、D 4组。A组术前2 h予以阿司匹林300 mg联合氯吡格雷300 mg鼻饲或纳肛,术后予以阿司匹林(100 mg/d)联合氯吡格雷(75 mg/d)口服,TEG检测时间为用药7 d左右。B组为口服阿司匹林(100 mg/d)联合氯吡格雷(75 mg/d)的患者。C组只服用阿司匹林(100 mg/d)。D组只服用氯吡格雷(75 mg/d)。比较各组间二磷腺苷酸(ADP)、花生四烯酸(AA)激活的血小板活性[MA(AA),MA(ADP)]和抑制率(AA%,ADP%)的差异和影响因素。结果A组的MA(AA)和MA(ADP)与其他组比较,差异有统计学意义(P<0.05);B组与C组的MA(AA)比较,差异有统计学意义(P=0.021);B组与D组的MA(ADP)和ADP%差异无统计学意义(P=0.264,P=0.254)。年龄、性别、体重是抗血小板药物疗效的影响因素,而用药时长与疗效无关。结论短期内大剂量使用抗血小板药物可以快速抗血小板防止栓塞,阿司匹林和氯吡格雷联合用药可以增强阿司匹林的抗血小板效果,对氯吡格雷无影响。体重会影响抗血小板药物的疗效,而用药时间长短不会改变药物效果。 Objective To evaluate the factors influencing the efficacy of antiplatelet drugs in patients with cardiovascular and cerebrovascular diseases.Methods From April 2020 to April 2021,363 patients who underwent thromboelastography and platelet map test in our hospital were divided into four groups A,B,C and D according to the type and amount of medication.Group A was given aspirin 300 mg combined with clopidogrel 300 mg nasogastrically or anally 2 hours before surgery,and aspirin(100 mg/d)combined with clopidogrel(75 mg/d)orally after surgery;TEG test time was around 7 days after medication.Group B were patients taking aspirin(100 mg/d)combined with clopidogrel(75 mg/d)orally.Group C were patients taking aspirin(100 mg/d)only.Group D were patients taking clopidogrel(75 mg/d)only.The differences in platelet activity(MA[AA],MA[ADP])and inhibition rate(AA%,ADP%),which activated by adenosine diphosphate(ADP)and arachidonic acid(AA)among the groups,and the factors affecting inhibition rate were compared.Results The MA(AA)and MA(ADP)of group A were significantly different from other groups(P<0.05),the MA(AA)between group B and group C were significantly different(P=0.021),and the MA(ADP)and ADP%between group B and group D were not significantly different(P=0.264,P=0.254).Age,gender and body weight were factors influencing the efficacy of antiplatelet drugs,while medication duration has no correlation with medication efficacy.Conclusion High doses of antiplatelet drugs taken in the short term can quickly prevent antiplatelet embolization,and the combination of aspirin and clopidogrel can enhance the antiplatelet effect of aspirin,while having no effect on clopidogrel.Age,sex or weight can affect the efficacy of antiplatelet drugs alone,while the duration of medication does not change the efficancy.
作者 朱雯雯 李莺 周小玉 ZHU Wenwen;LI Ying;ZHOU Xiaoyu(Department of Blood Transfusion,the First Affiliated Hospital of Nanjing Medical University,Nanjing,210029,China)
出处 《临床血液学杂志》 CAS 2023年第4期225-230,共6页 Journal of Clinical Hematology
关键词 血栓弹力图 阿司匹林 氯吡格雷 thromboelastography aspirin clopidogrel
  • 相关文献

参考文献7

二级参考文献81

  • 1Gergely Feher,Andrea Feher,Gabriella Pusch,Katalin Koltai,Antal Tibold,Beata Gasztonyi,Elod Papp,Laszlo Szapary,Gabor Kesmarky,Kalman Toth.Clinical importance of aspirin and clopidogrel resistance[J].World Journal of Cardiology,2010,2(7):171-186. 被引量:36
  • 2Mastalerz L.,Setkowicz M.,Sanak M.,A. Szczeklik,王琼.阿司匹林诱发荨麻疹和白三烯C4合酶等位基因变异的家族性聚集[J].世界核心医学期刊文摘(皮肤病学分册),2006,2(6):21-22. 被引量:3
  • 3Savi P, Pereillo JM, Uzabiaga MF, et al. Identifica- tion and biological activity of the active metabolite of clopidogrel [ J ]. Thromb Haemost, 2000, 84 ( 5 ) : 891-896.
  • 4Komosa A, Lesiak M, Siniawski A, et al. Signifi- cance of antiplatelet therapy in emergency myocardial infarction treatment [ J ]. Postepy Kardiol Interwen- cyjnej, 2014, 10(1) ~ 32-39.
  • 5Kushner FG, Hand M, Smith SC Jr, et al. 2009 Fo- cused Updates : ACC/AHA Guidelines for the Manage- ment of Patients With ST-Elevation Myocardial Infarc- tion (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percuta- neous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update) : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [ J ]. Circulation, 2009, 120 (22) : 2271-2306.
  • 6Snoep JD, Hovens MM, Eikenboom JC, et al. Clopi- dogrel nonresponsiveness in patients undergoing percu- taneous coronary intervention with stenting: a system- atic review and meta-analysis[ J]. Am Heart J, 2007, 154(2) : 221-231.
  • 7Ades PA, Savage PD, Toth M J, et al. The influence of obesity and consequent insulin resistance on coro- nary risk factors in medically treated patients with cor- onary disease [ J 3- Int J Obes ( Lond), 2008, 32 (6) : 967-974.
  • 8Andersson C, Lyngbrek S, Nguyen CD, et al. Associ- ation of elopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction inpatients with and without diabetes [ J ]. JAMA, 2012, 308 (9) : 882-889.
  • 9Lundstr~m A, Laska AC, Von Arbin M, et al. Glu- cose intolerance and insulin resistance as predictors of low platelet response to clopidogrel in patients with mi- nor ischemic stroke or TIA [ Jl. Platelets, 2014, 25 (2) : 102-110.
  • 10Pankert M, Quilici J, Loundou AD, et al. Impact of obesity and the metabolic syndrome on response to clo- pidogrel or prasugrel and bleeding risk in patients trea- ted after coronary stenting[ J]. Am J Cardiol, 2014, 113(1) : 54-59.

共引文献62

同被引文献99

引证文献6

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部